Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial

Forlani, L; De Cecco, L; Simeon, V; Paolini, B; Bagnoli, M; Cecere, SC; Spina, A; Citeroni, E; Bignotti, E; Lorusso, D; Arenare, L; Russo, D; De Angelis, C; Ardighieri, L; Scognamiglio, G; Del Sesto, M; Tognon, G; Califano, D; Schettino, C; Chiodini, P; Perrone, F; Mezzanzanica, D; Pignata, S; Tomassetti, A

Mezzanzanica, D; Tomassetti, A (通讯作者)，Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol, Integrated Biol Rare Tumors, Milan, Italy.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2023; 42 (1):

Abstract

BackgroundValidated prognostic biomarkers for anti-angiogenic therapy using the anti-VEGF antibody Bevacizumab in ovarian cancer (OC) patients are sti......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索